Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C., Fontan, J., Garderet, L., Jie, K., Karlin, L., Kuhnowski, F., Lambert, J., Leleu, X., Lenain, P., Macro, M., Mathiot, C., Orsini-Piocelle, F., Perrot, A., Stoppa, A., van de Donk, N. W., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J., Meuleman, N., Vekemans, M., Westerman, M., Klein, S. K., Levin, M., Fermand, J. P., Escoffre-Barbe, M., Eveillard, J., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., de Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet-Loiseau, H., & Sonneveld, P. (2019). bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet, 394(10192), 29–38. http://access.bl.uk/ark:/81055/vdc_100086830540.0x00004e